Eli Lilly's (LLY -2.2%) Forteo and risedronate, which is marketed by Warner Chilcott (WCRX...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly's (LLY -2.2%) Forteo and risedronate, which is marketed by Warner Chilcott (WCRX +3.85%) and Sanofi (SNY +0.8%), go head to head in a Phase III trial of postmenopausal women with osteoporotic vertebral fractures and come out equal in the main goal of achieving a 30%+ fall in the worst back pain. (PR)